Pursuing a healthy 100-year-old life
through the microbiota

Total Health Care

Care aNd

DCNBio develops and produces Saccharomyces boulardii which is most clinically proven probiotics and is researching next-generation probiotics by regulating enzyme activity and identifying immune-modulating probiotics products.

Through this, we will develop a microbiota-derived therapeutic product that can be applied not only for gastrointestinal diseases but also for metabolic and degenerative brain diseases based on the Microbiome-Gut-Brain Axis.

In addition, we will lead the era of personalized medicine by using gut microbiota analysis and developing a fecal microbiota functional analyzer.


Seung Sik, LeeCEO
  • National Chonnam University
  • Head of Probiotics business, Ildong Pharmaceutical
  • Established Ildong Bioscience
Seung Sik, Lee CEO
Sang Mo, ChangCFO
  • Korea University
  • Industrial Bank of Korea
  • Yunhap Capital
Sang Mo, Chang CFO
Si Hyun, KimCMO
  • CHUNG-ANG University
  • Hyundai Motors Service Engineer
  • Cummins Korea CS Manager
  • Bosch Korea Key Account Manager
  • Delphi Korea Country Manager
Si Hyun, Kim CMO
Yong Sung, KimCTO/CRO
  • M.D., Wonkwang University College of Medicine
  • Ph.D., Catholic University Graduate school
  • Former professor, Gastroenterology, Wonkwang University College of Medicine
  • Post-Doctoral fellowship, UCLA, Digestive diseases research center,
    Center for neurobiology of stress
  • Basic section editor, J Neurogastroenterol Motil
  • Scientific committee, Asian Neurogastroenterolgy and Motility Association,
    Korean Society of Neurogastroenterology
Yong Sung, Kim CTO/CRO


Heung Chae, Chung
Technical advisor /
Advisor stockholder
  • Master of Biotechnology, KAIST
  • Ph.D. Biotech, France
  • Korea Research Institute of Bioscience and Biotechnology Senior
  • Researcher, Biosynthesis Research Center
  • Founding member of GenoFocus (Main Shareholder)
Tatsuya Unno
Academic (Basic) Advisory /
Professor (Jeju Univ.)
  • Tokyo University
  • Ph.D., Gwangju Institute of Science and Technology
  • University of Minnesota
  • Professor of Jeju National University, School of Life Sciences
Sang Hyun, Kim
Academic (Clinical) Advisory /
Professor (Seoul Univ.)
  • Doctor of Medicine, Seoul National Univ.
  • Professor, Cardiology, Seoul National Univ. College of Medicine (Boramae Hospital)
  • USMD
Joo Sung, Kim
Academic (Clinical) Advisory /
Professor (Seoul Univ.)
  • M.D., Seoul National University College of Medicine
  • Ph.D., Seoul National University, Graduate school
  • Professor, Gastroenterology, Seoul National University College of Medicine
  • President, Gangnam Center, Seoul National University Hospital
Ha Young, Kim
Academic (Clinical) Advisory /
Professor (Ulsan Univ.)
  • M.D., Chonnam National University College of Medicine
  • Ph,.D,, University of Ulsan Graduate school
  • Professor of Endocrinology, University of Ulsan College of Medicine (Gangneung Asan Hospital)
  • Loma Linda University, Musculoskeletal Disease Center

Business Area

Production of Yeast Probiotics
DCNBio aims to lead the domestic yeast probiotic market by developing S.
boulardii, which relies entirely on imports from overseas. DCNBio has
developed the technology for mass production of S. boulardii by specialized
fermentation and drying methods.
Global Exportation
DCNbio is a specialized probiotic company that exports probiotics to the
worldwide global market through DNCbio's unique sales network connected to
China, Russia, and Southeast Asia.
Development of therapeutic product using S. boulardii
Beyond the digestive diseases such as pediatric diarrhea, we are trying to
expand the therapeutic indication to metabolic syndromes such as
non-alcoholic fatty liver and hypercholesterolemia.
Personalized medicine by gut microbiota analysis
DCNbio recognizes the importance of personalized medicine. We are analyzing
individual gut microbiota with the latest techniques such as next-generation
sequencing and providing customized probiotics
Products for pet health
We have developed probiotics and diet supplements for the health of pets.

Primary R&D

Next Generation Probiotics of
S. boulardii
and other probiotics
  • Genetic engineering technology
  • Selective activation of bacterial/fungal enzyme technology
  • Development of immune-modulating paraprobiotics
Development of pharmabiotics of degenerative
brain diseases on the microbiome-gut-brain axis
  • Clinical Study on the Role of gut microbiota in Korean patients with
    Parkinson’s disease
    (2nd half of 2019 ~ 1st half of 2020, Department of Neurology & Digestive
    Disease Research Institute, Wonkwang University Hospital, Iksan, Korea)
  • Selection of candidate strains for pharmabiotics from
    <KRIBB Korean healthy library> based on the clinical research.
  • Preclinical in vitro and in vivo study
    (Wonkwang Digestive Diseases Research Institute)
Development of personal fecal microbiota
functional analyzer
  • Development of portable and simple gut microbiota functional
    analyzer using stool.
  • It can replace the conventional analysis methods for the function of
    gut microbiota and their metabolites that can only be performed
    with large-scale equipment.
Investigating pharmabiotics candidates
for functional gastrointestinal disorders
with food big data
  • Collaboration with Gut & Food Healthcare,
    which is a digital
    therapeutics start-up company for patients with functional
    gastrointestinal disorders and has collected big data about the
    symptom and food relationship.

R&D Center

Affiliated Research Institute
(to be established in 2020)
DCNbio Research Center in KRIBB

Number of Researchers: 1 doctoral student,
1 master's student, etc. (Total 3~4 people)

181, Yeopsin-gil, Jeongeup-si, Jeollabuk-do
Cooperating Research Institute
Digestive Disease Research Institute,
College of Medicine, Wonkwang University

Director: Moon-Young Lee M.D.,Ph.D., Department of Physiology,
Wonkwang University School of Medicine
Workforce: 1 M.D./Ph.D. 1 M.D./MSc.,1, 1 Ph.D., 1 MSc.,
1 Researcher

518, Iksan-daero, Iksan-si, Chonbuk, Korea
Cooperating Research Institute
KRIBB Jeonbuk Branch Microbial
Function Research Center

Jaejun Song Dr. LAB

181, Yeopsin-gil, Jeongeup-si, Jeollabuk-do


DCN bio Seoul

101-5, GBSA ,1 FL, KT Bundang Bldg, 779-6 Seongnam-ro, Bundang-gu, Seongnam-si,
Gyeonggi-do, Korea

Tel. 00-000-0000 / Fax. 00-000-0000

E-mail. sslee@dcnbio.com


We welcome all inquiries from all business sectors who want to lead the era of personalized medicine
for the future with DC Health Bio, the Total Health Care Company that realizes 100 years of
health through microbiome. Search for a way for business / cooperation through inquiry.
Contact us